About: Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Catechins may influence both desirable and undesirable effects of many drugs. In this study, the in vitro effect of (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate (EGCG) on the efficacy of anticancer drug doxorubicin (DOX) was studied in HCT-8 cancer cells. Rat hepatocytes were used to study the influence of EGCG on DOX hepatotoxicity. Cell proliferation and viability were studied by 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide and neutral red uptake test assays. Formation of reactive oxygen species (ROS) was determined using the dichlorofluorescein assay. All of the studied catechins (1-25 mu mol L-1) had no effect on the proliferation of intestinal cancer cells and did not affect the antiproliferative effect of DOX (1-8 mu mol L-1) in these cells. Moreover, EGCG at 25 mu mol L-1 increased the viability of isolated hepatocytes and significantly protected these cells against DOX-induced toxicity and ROS production. Consumption of EGCG during DOX therapy seems to be safe and beneficial, since EGCG does not decrease DOX anticancer efficacy and could ameliorate DOX hepatotoxicity.
  • Catechins may influence both desirable and undesirable effects of many drugs. In this study, the in vitro effect of (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate (EGCG) on the efficacy of anticancer drug doxorubicin (DOX) was studied in HCT-8 cancer cells. Rat hepatocytes were used to study the influence of EGCG on DOX hepatotoxicity. Cell proliferation and viability were studied by 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide and neutral red uptake test assays. Formation of reactive oxygen species (ROS) was determined using the dichlorofluorescein assay. All of the studied catechins (1-25 mu mol L-1) had no effect on the proliferation of intestinal cancer cells and did not affect the antiproliferative effect of DOX (1-8 mu mol L-1) in these cells. Moreover, EGCG at 25 mu mol L-1 increased the viability of isolated hepatocytes and significantly protected these cells against DOX-induced toxicity and ROS production. Consumption of EGCG during DOX therapy seems to be safe and beneficial, since EGCG does not decrease DOX anticancer efficacy and could ameliorate DOX hepatotoxicity. (en)
Title
  • Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro
  • Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro (en)
skos:prefLabel
  • Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro
  • Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro (en)
skos:notation
  • RIV/00216208:11160/14:10281583!RIV15-MSM-11160___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, P(EE2.3.30.0022), P(GBP303/12/G163)
http://linked.open...iv/cisloPeriodika
  • 2
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 13485
http://linked.open...ai/riv/idVysledku
  • RIV/00216208:11160/14:10281583
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • doxorubicin; hepatocytes; HCT-8 cells; chemoprevention; epigallocatechin gallate (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • CR - Kostarická republika
http://linked.open...ontrolniKodProRIV
  • [EC47CE4EE605]
http://linked.open...i/riv/nazevZdroje
  • Acta Pharmaceutica
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 64
http://linked.open...iv/tvurceVysledku
  • Boušová, Iva
  • Hanušová, Veronika
  • Skálová, Lenka
  • Matoušková, Petra
  • Bártíková, Hana
  • Rudolfová, Petra
http://linked.open...ain/vavai/riv/wos
  • 000337705100005
issn
  • 1330-0075
number of pages
http://bibframe.org/vocab/doi
  • 10.2478/acph-2014-0018
http://localhost/t...ganizacniJednotka
  • 11160
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 35 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software